If you or someone you know has experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering whether these symptoms could signal gastroparesis. Within the tradition of carefully contextualizing pharmaceutical side effects, this page reviews documented reports and clinical evaluation pathways for Ozempic-associated gastroparesis in New York.
Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or even surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacology involves mimicking the action of endogenous GLP-1, which stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying. This latter effect is central to its therapeutic action but also underlies many of its gastrointestinal adverse effects. The prescribing information for Ozempic reports that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo, with rates of 32.7% for the 0.5 mg dose and 36.4% for the 1 mg dose, compared to 15.3% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients included nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
The mechanistic pathway linking Ozempic to gastroparesis is rooted in its effect on gastric motility. GLP-1 receptor agonists delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to prolonged retention of gastric contents. In susceptible individuals, this pharmacological effect may exacerbate or unmask underlying gastroparesis, resulting in severe and persistent symptoms. While the prescribing information does not explicitly list gastroparesis as a specific adverse reaction, the high rates of nausea, vomiting, and abdominal pain—symptoms that overlap with gastroparesis—suggest a potential association. The label does include warnings about serious hypersensitivity reactions, such as anaphylaxis and angioedema, but does not specifically address the risk of gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This lack of explicit warning may be relevant to settlement considerations, as affected patients could argue that the risks were not adequately communicated.
For patients in New York who have developed gastroparesis after using Ozempic, understanding the statute of limitations is critical for any potential legal action. In New York, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. This 'discovery rule' is particularly important in cases where the harm—such as gastroparesis—may develop gradually or be initially attributed to other causes. The timeline between exposure to Ozempic and documented harm is a key factor. Given that gastrointestinal adverse reactions often occur during dose escalation, patients may experience symptoms within weeks to months of starting the medication. However, the diagnosis of gastroparesis may be delayed due to the need for specialized testing, such as gastric emptying scintigraphy, and the overlap of symptoms with other conditions. Patients should document the date of first use of Ozempic, the onset of symptoms, and the date of formal diagnosis to establish the timeline.
Settlement-related considerations for affected patients include the adequacy of warnings provided by the manufacturer. The prescribing information for Ozempic highlights gastrointestinal adverse reactions but does not specifically warn about gastroparesis. This omission may be central to claims that the manufacturer failed to adequately inform patients and healthcare providers of the risk. Additionally, the severity and persistence of gastroparesis symptoms, which can lead to malnutrition, weight loss, and reduced quality of life, may influence the value of any settlement. Patients should consult with a legal professional experienced in pharmaceutical litigation to evaluate their case and ensure compliance with New York's statute of limitations. In summary, the evidence indicates a plausible link between Ozempic and gastroparesis through its mechanism of delayed gastric emptying, supported by clinical trial data showing elevated rates of gastrointestinal adverse reactions. The lack of explicit warnings about gastroparesis in the prescribing information may be a factor in settlement discussions. New York patients must be aware of the three-year statute of limitations, which begins from the discovery of the injury, and should seek timely legal advice to preserve their rights.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In New York, the statute of limitations for personal injury claims, including those related to pharmaceutical products like Ozempic, is generally three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. This discovery rule is crucial for conditions like gastroparesis that may develop gradually.
No, the prescribing information for Ozempic does not explicitly list gastroparesis as a specific adverse reaction. It does report high rates of gastrointestinal adverse reactions such as nausea, vomiting, and abdominal pain, which overlap with gastroparesis symptoms, but does not specifically warn about gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Ozempic exposure and a related diagnosis may request an independent, no-cost eligibility review.